论文部分内容阅读
目的 :观察苯扎贝特降低血脂的疗效。方法 :治疗组 4 1例 (男性 2 5例 ,女性 16例 ;年龄 64±s 8a)给苯扎贝特 0 .2 g ,po ,tid× 4wk。对照组 35例(男性 14例 ,女性 2 1例 ;年龄 61± 7a)给阿西莫司0 .2 5g ,po ,tid× 4wk。结果 :苯扎贝特降低血胆固醇 (TC)和三酰甘油 (TG)的总有效率为 84 %和88%。阿西莫司降低血TC和TG的总有效率为77%和 67%。 2药且均有升高高密度脂蛋白胆固醇、载脂蛋白AI/载脂蛋白B10 0 的作用 ,苯扎贝特降低TG的水平高于阿西莫司 (P <0 .0 5)。结论 :苯扎贝特是一个安全、有效的降脂药物 ,特别适用于高TG的治疗
Objective: To observe the effect of bezafibrate on lowering blood lipid. Methods: In the treatment group, 41 cases (25 males and 16 females; age 64 ± s 8a) were given bezafibrate 0.2 g, po, tid × 4 weeks. The control group of 35 patients (14 males and 21 females; age 61 ± 7a) were given 0.252 g pox, po, tid × 4 weeks. Results: The total effective rate of bezafibrate lowering blood cholesterol (TC) and triglyceride (TG) was 84% and 88%. The total effective rate of aspirin in lowering blood TC and TG was 77% and 67%, respectively. 2 drugs and increased high-density lipoprotein cholesterol, apolipoprotein AI / apolipoprotein B10 0 role, bezafibrate levels of TG lower than asarimus (P <0.05). Conclusion: Bezafibrate is a safe and effective lipid-lowering drug and is especially suitable for the treatment of high TG